摘要
背景:将抗癌药物包含在生物相容性纳米颗粒载体中,由于可溶性循环游离药物的减少,降低了一般毒性并提高了临床治疗的疗效。 方法:此外,从废水中去除新出现的药物污染物是必须认真对待的。氮化硼 (BN) 是药物递送的一种选择,因为它具有许多令人惊讶的特性。在这里,制备了氮化硼纳米粒子,通过傅里叶变换红外光谱 (FT-IR) 和 X 射线衍射 (XRD) 进行表征,并用于递送美法仑抗癌药物。 结果:然后,进行密度泛函理论 (DFT) 计算以研究该药物通过熟悉的杂化泛函 B3LYP 和 B3PW91 在纯氮化硼富勒烯表面的吸附。此外,极化连续介质模型 (PCM) 计算表明 BN 在水中是稳定的。 结论:最后,在 ES-2 癌细胞上检查了 BN 纳米颗粒的体外细胞毒性和活力。该材料的抑制剂量 IC50 证实了可接受的细胞毒性和纳米颗粒影响 ES-2 癌细胞的平均生长。
关键词: 美法仑、吸附、DFT法、氮化硼富勒烯、抗卵巢癌药物、PCM。
Current Molecular Medicine
Title:Studying Adsorption and Cellular Toxicity of Boron Nitride Nanostructure versus Melphalan Anti-ovarian Cancer Drug
Volume: 21 Issue: 8
关键词: 美法仑、吸附、DFT法、氮化硼富勒烯、抗卵巢癌药物、PCM。
摘要:
Background: Inclusion of anticancer drugs into biocompatible nanoparticulate carriers decreases the general toxicity and improves the efficacy of clinical treatments due to the reduction of soluble circulating free drugs.
Methods: In addition, removal of emerging drug contaminants from wastewaters is a necessity that should be seriously attended. Boron nitride (BN) is a choice in drug delivery because of its many surprising properties. Here, boron nitride nanoparticles are prepared, characterized by Fourier-transform infrared spectroscopy (FT-IR) and x-ray diffraction (XRD) and used in the delivery of melphalan anti-cancer drug.
Results: Then, density functional theory (DFT) calculations are carried out to study the adsorption of this drug on the surface of pure boron nitride fullerene via familiar hybrid functionals B3LYP and B3PW91. In addition, the polarizable continuum model (PCM) calculations show that BN is stable in water.
Conclusion: Finally, the in vitro cellular toxicity and viability of BN nanoparticles was examined on ES-2 cancer cells. The inhibitory dose IC50 of the material confirmed acceptable cytotoxicity and nanoparticles affected the average growth of the ES-2 cancer cells.
Export Options
About this article
Cite this article as:
Studying Adsorption and Cellular Toxicity of Boron Nitride Nanostructure versus Melphalan Anti-ovarian Cancer Drug, Current Molecular Medicine 2021; 21 (8) . https://dx.doi.org/10.2174/1566524021666210111104428
DOI https://dx.doi.org/10.2174/1566524021666210111104428 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Privileged 1,2,4-Oxadiazoles in Anticancer Drug Design: Novel 5- Aryloxymethyl-1,2,4-oxadiazole Leads for Prostate Cancer Therapy
Letters in Drug Design & Discovery Astatine-211: Production and Availability
Current Radiopharmaceuticals Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Evidence for Predominance of CCR5-Using HIV-1 Strains During Highly Active Antiretroviral Therapy
Current HIV Research New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Antigene and Antiproliferative Effects of Triplex-Forming Oligonucleotide (TFO) Targeted on hmgb1 Gene in Human Hepatoma Cells
Anti-Cancer Agents in Medicinal Chemistry Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Recent Patents on Anti-Cancer Drug Discovery Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Current Pharmaceutical Design Natural Plant Extracts as Potential Therapeutic Agents for the Treatment of Cancer
Current Topics in Medicinal Chemistry Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials Pharmacotherapy & Surgical Interventions Available for Obesity Management and Importance of Pancreatic Lipase Inhibitory Phytomolecules as Safer Anti-Obesity Therapeutics
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Current Medicinal Chemistry Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry Effect of Local Paclitaxel Delivery Following Stenting on Restenosis andMorphology in the Porcine Coronary Artery
Vascular Disease Prevention (Discontinued)